1. Medical Insurance Region Code Drug Name Dosage Form Drug Category National Medical Insurance (2021 Edition) 95 (Negotiation) Gadoteridol Injection Miscellaneous gt; contrast agent gt; magnetic resonance imaging contrast agent (XVgt; XV08gt; Disease treatment drugs (XVgt; XV03gt; XV03Agt; Other therapeutic drugs gt; drugs for treating hyperkalemia and hyperphosphatemia (XVgt; XV03gt; XV03Agt; Suspended-release dosage forms miscellaneous gt; other therapeutic drugs gt; other therapeutic drugs gt; iron chelators (XVgt; XV03gt; XV03Agt; ;Ophthalmic drugsgt; Ocular vascular disease drugs (XSgt; XS01gt; Ophthalmic drugs gt; Ocular vascular disease drugs (XSgt; XS01gt; Medications gt; Medications for Ocular Vascular Diseases (XSgt; XS01gt; gt; Ocular vascular disease drugs (XSgt; XS01gt; ; XS01gt; Other systemic drugs for tract diseasesgt; leukotriene receptor antagonists (XRgt; XR03gt; XR03Dgt; Glycopyrrolate inhalation powder spray capsule respiratory system gt; drugs for obstructive airway diseases gt; inhaled adrenergic drugs (XRgt; XR03gt; XR03A)
10. Category B National Medical Insurance (2021 Edition) 84 (Negotiation) Umeclidinium Bromide Vilanterol Inhalation Powder Aerosol Respiratory System gt; Drugs for Obstructive Airway Diseases gt; Inhaled Adrenergic Drugs (XRgt; XR03gt; XR03A ) Category B National Medical Insurance (2021 Edition) 83 (Negotiation) Urrexin Injection Nervous System Drugs gt; Other Nervous System Drugs gt; Other Nervous System Drugs (XNgt; XN07gt; XN07X) Category B National Medical Insurance (2021 Edition) 82 ( Negotiation) Paroxetine enteric-coated extended-release tablets nervous system drugs gt; psychostimulants gt; antidepressants gt; selective serotonin reuptake inhibitors (XNgt; XN06gt; XN06Agt; XN06AB)
11 , Category B National Medical Insurance (2021 Edition) 81 (Negotiation) Quetiapine sustained-release controlled-release dosage form of nervous system drugs gt; neuroleptic drugs gt; antipsychotic drugs
gt; diazepines, noroxydiazepines and dithiazepines (XNgt; XN05gt; XN05Agt; Lidocaine gel patch nervous system drugs gt; anesthetics gt; local anesthetics gt; amides (XNgt; XN01gt; XN01Bgt; and immunomodulators gt; immunosuppressants gt; immunosuppressants gt; tumor necrosis factor alpha (TNF-α) inhibitors (XLgt; XL04gt; XL04Agt; 2021 Edition) 78 (Negotiation) Adalimumab Injection Antineoplastic Drugs and Immunomodulatorsgt; Immunosuppressantsgt; Immunosuppressantsgt; Tumor necrosis factor alpha (TNF-α) inhibitors (XLgt; XL04gt; XL04Agt; XL04AB ) Class B National Medical Insurance (2021 Edition) 77 (Negotiation) Everolimus Oral Sustained Release Dosage Antineoplastic Drug and Immunomodulatorgt; Immunosuppressant gt; Immunosuppressant gt; Selective Immunosuppressant (XLgt; XL04gt; XL04Agt; gt; selective immunosuppressant (XLgt; The final "Catalogue" contains 2,800 types of medicines, including 1,426 types of Western medicines and 1,374 types of Chinese patent medicines. The proportion of Chinese and Western medicines is basically the same. The new version of the medical insurance catalog contains 2,643 types of medicines, including 1,322 Western medicines. There are 1,321 Chinese patent medicines, and the Chinese medicine preparations are managed according to the access method. There are 892 drugs included in the routine admission. There is a basic balance between Chinese and Western medicines. The number of Class A drugs has increased appropriately, compared with 2017. 46 items were added in the year, including 398 western medicines and 242 Chinese patent medicines.
2. In order to better meet the needs of clinical rational drug use, 148 new items were added to the routine access part of the catalog this time. Among them, there are 47 western medicines and 101 Chinese patent medicines. The new medicines cover priority national essential medicines, medicines for treating major diseases such as cancer and rare diseases, medicines for chronic diseases, and medicines for children. There are 5 drugs for the treatment of major diseases, 36 drugs for chronic diseases such as diabetes, and 38 drugs for children. Most of the national essential drugs have passed routine access or been included in the list of drugs to be negotiated, and 74 essential drugs have been adjusted from Category B to Category A. .